Is BellRing Brands (BRBR) Stock Outpacing Its Medical Peers This Year?

Zacks
08 Oct 2024

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is BellRing Brands (BRBR) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.

BellRing Brands is a member of our Medical group, which includes 1025 different companies and currently sits at #2 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.

The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. BellRing Brands is currently sporting a Zacks Rank of #1 (Strong Buy).

Over the past three months, the Zacks Consensus Estimate for BRBR's full-year earnings has moved 1.2% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.

Based on the most recent data, BRBR has returned 11.8% so far this year. Meanwhile, stocks in the Medical group have gained about 6.2% on average. This means that BellRing Brands is outperforming the sector as a whole this year.

One other Medical stock that has outperformed the sector so far this year is Aclaris Therapeutics (ACRS). The stock is up 9.5% year-to-date.

Over the past three months, Aclaris Therapeutics' consensus EPS estimate for the current year has increased 16.3%. The stock currently has a Zacks Rank #2 (Buy).

To break things down more, BellRing Brands belongs to the Medical - Products industry, a group that includes 88 individual companies and currently sits at #60 in the Zacks Industry Rank. Stocks in this group have gained about 11.1% so far this year, so BRBR is performing better this group in terms of year-to-date returns.

In contrast, Aclaris Therapeutics falls under the Medical - Drugs industry. Currently, this industry has 171 stocks and is ranked #88. Since the beginning of the year, the industry has moved -4.6%.

BellRing Brands and Aclaris Therapeutics could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

BellRing Brands Inc. (BRBR) : Free Stock Analysis Report

Aclaris Therapeutics, Inc. (ACRS) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10